SIRPA and neoplasm: IMM0306 has stronger ADCC activity compared to rituximab, stronger ADCC and ADCP compared to SIRPα-Fc, very low binding activities on human RBCs to avoid potential human cell toxicities, and a higher affinity to CD20 for strong tumor cell killing.